163 related articles for article (PubMed ID: 37386497)
1. Pharmacological targeting of one‑carbon metabolism as a novel therapeutic strategy for glioblastoma.
Sun Y; Mu G; Xue Z; Li X; Lin X; Han M
J Transl Med; 2023 Jun; 21(1):424. PubMed ID: 37386497
[No Abstract] [Full Text] [Related]
2. Serine, glycine and one‑carbon metabolism in cancer (Review).
Pan S; Fan M; Liu Z; Li X; Wang H
Int J Oncol; 2021 Feb; 58(2):158-170. PubMed ID: 33491748
[TBL] [Abstract][Full Text] [Related]
3. Targeting cellular respiration as a therapeutic strategy in glioblastoma.
Shang E; Nguyen TTT; Westhoff MA; Karpel-Massler G; Siegelin MD
Oncotarget; 2023 May; 14():419-425. PubMed ID: 37141415
[TBL] [Abstract][Full Text] [Related]
4. Microbial one‑carbon and nitrogen metabolisms are beneficial to the reservoir recovery after cyanobacterial bloom.
Yu Z; Peng X; Liu L; Yang JR; Zhai X; Xue Y; Mo Y; Yang J
Sci Total Environ; 2023 Jan; 856(Pt 1):159004. PubMed ID: 36155037
[TBL] [Abstract][Full Text] [Related]
5. Tumor targeting peptides: novel therapeutic strategies in glioblastoma.
Raucher D
Curr Opin Pharmacol; 2019 Aug; 47():14-19. PubMed ID: 30776641
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological targeting of the tumor-immune symbiosis in glioblastoma.
Pang L; Khan F; Dunterman M; Chen P
Trends Pharmacol Sci; 2022 Aug; 43(8):686-700. PubMed ID: 35534356
[TBL] [Abstract][Full Text] [Related]
7. Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies.
Roth P; Weller M
Neuro Oncol; 2014 Oct; 16 Suppl 8(Suppl 8):viii14-9. PubMed ID: 25342600
[TBL] [Abstract][Full Text] [Related]
8. The pro-tumorigenic effects of metabolic alterations in glioblastoma including brain tumor initiating cells.
Landis CJ; Tran AN; Scott SE; Griguer C; Hjelmeland AB
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):175-188. PubMed ID: 29378228
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological Strategy for Selective Targeting of Glioblastoma by Redox-active Combination Drug - Comparison With the Chemotherapeutic Standard-of-care Temozolomide.
Sumiyoshi A; Shibata S; Zhelev Z; Miller T; Lazarova D; Zlateva G; Aoki I; Bakalova R
Anticancer Res; 2021 Dec; 41(12):6067-6076. PubMed ID: 34848461
[TBL] [Abstract][Full Text] [Related]
10. Effect of the one‑carbon unit cycle on overall DNA methylation in children with Down's syndrome.
Song C; He J; Chen J; Liu Y; Xiong F; Wang Y; Li T
Mol Med Rep; 2015 Dec; 12(6):8209-14. PubMed ID: 26497014
[TBL] [Abstract][Full Text] [Related]
11. FGF2: a novel druggable target for glioblastoma?
Jimenez-Pascual A; Mitchell K; Siebzehnrubl FA; Lathia JD
Expert Opin Ther Targets; 2020 Apr; 24(4):311-318. PubMed ID: 32174197
[No Abstract] [Full Text] [Related]
12. Targeting Protein Kinases for the Treatment of Glioblastoma Multiforme: Linking Basic Studies to Clinical Applications.
Zhou A
Curr Pharm Des; 2017 Nov; 23(29):4290-4302. PubMed ID: 28699529
[TBL] [Abstract][Full Text] [Related]
13. Salinomycin encapsulated nanoparticles as a targeting vehicle for glioblastoma cells.
Tığlı Aydın RS; Kaynak G; Gümüşderelioğlu M
J Biomed Mater Res A; 2016 Feb; 104(2):455-64. PubMed ID: 26476239
[TBL] [Abstract][Full Text] [Related]
14. Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells.
Wang X; Yang K; Wu Q; Kim LJY; Morton AR; Gimple RC; Prager BC; Shi Y; Zhou W; Bhargava S; Zhu Z; Jiang L; Tao W; Qiu Z; Zhao L; Zhang G; Li X; Agnihotri S; Mischel PS; Mack SC; Bao S; Rich JN
Sci Transl Med; 2019 Aug; 11(504):. PubMed ID: 31391321
[TBL] [Abstract][Full Text] [Related]
15. Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies.
Agnihotri S; Burrell KE; Wolf A; Jalali S; Hawkins C; Rutka JT; Zadeh G
Arch Immunol Ther Exp (Warsz); 2013 Feb; 61(1):25-41. PubMed ID: 23224339
[TBL] [Abstract][Full Text] [Related]
16. Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms.
Ariey-Bonnet J; Berges R; Montero MP; Mouysset B; Piris P; Muller K; Pinna G; Failes TW; Arndt GM; Morando P; Baeza-Kallee N; Colin C; Chinot O; Braguer D; Morelli X; André N; Carré M; Tabouret E; Figarella-Branger D; Le Grand M; Pasquier E
EBioMedicine; 2023 Sep; 95():104752. PubMed ID: 37572644
[TBL] [Abstract][Full Text] [Related]
17. Perhexiline Demonstrates FYN-mediated Antitumor Activity in Glioblastoma.
Kant S; Kesarwani P; Guastella AR; Kumar P; Graham SF; Buelow KL; Nakano I; Chinnaiyan P
Mol Cancer Ther; 2020 Jul; 19(7):1415-1422. PubMed ID: 32430486
[TBL] [Abstract][Full Text] [Related]
18. Identification of a natural inhibitor of methionine adenosyltransferase 2A regulating one-carbon metabolism in keratinocytes.
Bai J; Gao Y; Chen L; Yin Q; Lou F; Wang Z; Xu Z; Zhou H; Li Q; Cai W; Sun Y; Niu L; Wang H; Wei Z; Lu S; Zhou A; Zhang J; Wang H
EBioMedicine; 2019 Jan; 39():575-590. PubMed ID: 30591370
[TBL] [Abstract][Full Text] [Related]
19. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis.
Guo D; Hildebrandt IJ; Prins RM; Soto H; Mazzotta MM; Dang J; Czernin J; Shyy JY; Watson AD; Phelps M; Radu CG; Cloughesy TF; Mischel PS
Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12932-7. PubMed ID: 19625624
[TBL] [Abstract][Full Text] [Related]
20. Targeting the NF-E2-related factor 2 pathway: a novel strategy for glioblastoma (review).
Zhu J; Wang H; Fan Y; Lin Y; Zhang L; Ji X; Zhou M
Oncol Rep; 2014 Aug; 32(2):443-50. PubMed ID: 24926991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
